Boston Scientific FDA Footprint: PMA, 510(k) & Recall Patterns
A data-driven regulatory profile of Boston Scientific's FDA clearances, PMA approvals, safety recalls, and manufacturing hubs in Minnesota, Rhode Island, Massachusetts, and Ireland.
Executive Summary
What does the FDA database reveal about Boston Scientific's medical device clearances, recalls, and manufacturing footprint?
Boston Scientific maintains a highly specialized, interventional-focused regulatory portfolio with key dominance in cardiovascular stents, pacemakers, and urology devices. According to computed aggregates from official FDA databases, Boston Scientific holds 864 active 510(k) clearances, 6,725 Premarket Approval (PMA) filings and supplements, and 1,340 associated recalls. The company's 510(k) clearances are concentrated in the Cardiovascular (397 clearances, or 45.9%) and Gastroenterology/Urology (266 clearances, or 30.8%) specialties, followed by General, Plastic Surgery (97 clearances, or 11.2%), led by peripheral angioplasty catheters (product code LIT, 68 clearances), biliary stents and dilators (product code FGE, 65 clearances), catheter guide wires (product code DQX, 47 clearances), and percutaneous catheters (product code DQY, 38 clearances). In the high-risk PMA sector, Boston Scientific's portfolio is focused on cardiac rhythm management and coronary interventions, led by implantable pacemakers (product code LWP, 1,178 filings), implantable cardioverter defibrillators (product code LWS, 863 filings), and drug-eluting coronary stents (product code NIQ, 641 filings).
This large footprint is accompanied by 1,340 FDA-registered recalls, with implantable pacemakers (product code LWP, 98 recalls), biliary stents (product code FGE, 75 recalls) and superficial femoral artery stents (product code NIP, 74 recalls) representing the highest recall frequencies. Geographically, Boston Scientific operates a global manufacturing and logistics footprint, with leading registered manufacturing hubs located in Saint Paul, Minnesota (531 listings), Coventry, Rhode Island (391 listings), Galway, Ireland (332 listings), and Marlborough, Massachusetts (256 listings).
Boston Scientific FDA Footprint at a Glance
- 510(k) clearances: 864 (Cardiovascular 397 / Gastroenterology, Urology 266 / General, Plastic Surgery 97)
- PMA approvals and supplements: 6,725 (led by pacemakers LWP — 1,178, ICDs LWS — 863, drug-eluting stents NIQ — 641)
- FDA-registered recalls: 1,340 (led by pacemakers LWP — 98, biliary stents FGE — 75, femoral stents NIP — 74)
- Establishment / device listings: 2,399 (Saint Paul, Coventry, Galway, and Marlborough lead)
- Defining 2025–2026 event: March 2026 Class I software/battery safety mode correction of ACCOLADE, ESSENTIO, PROPONENT, and ALTRUA 2 pacemaker families
- Peer comparison position: Strongest specialization in interventional cardiology and urological devices among major medical device manufacturers
Introduction: The Interventional Focus of Boston Scientific
Boston Scientific is a global leader in medical technology, specializing in minimally invasive interventional therapies. The company operates through two main segments: MedSurg (which includes Endoscopy, Urology and Pelvic Health, and Neuromodulation) and Cardiovascular (which includes Cardiology and Peripheral Interventions). Its technologies are designed to replace open surgical procedures with catheter-based, less invasive alternatives, reducing recovery times and improving patient outcomes.
For hospital value-analysis committees, clinical engineers, and regulatory compliance teams, Boston Scientific is a key vendor. The company's products are highly specialized, meaning its regulatory risk is concentrated in high-value, high-risk clinical fields like electrophysiology, interventional cardiology, and pelvic health. Managing vendor risk requires an understanding of how Boston Scientific's FDA submissions and safety notices are distributed.
This report analyzes Boston Scientific's active 510(k) clearances, Premarket Approval (PMA) history, product recalls, and international manufacturing registrations. Using computed aggregates from the official FDA databases, we detail the specific product codes, clinical trends, and global supply chain sites that shape Boston Scientific's regulatory profile.
How These Numbers Were Computed
The figures in this dossier are aggregates computed from four public FDA datasets extracted in June 2026: the 510(k) database, the PMA database, the medical device recalls database, and the Establishment Registration and Device Listing database. Counts are produced by grouping records under Boston Scientific's brand and its registered medical-device subsidiaries — for Boston Scientific this includes its core divisions and major acquisitions (such as Guidant's cardiac rhythm management business, BTG interventional medicine, and recent structural heart/neuromodulation acquisitions) that operate under the corporate umbrella. Because legacy submissions often retain their original applicant name, clearances are counted across those entity names, while current establishment listings are attributed to the operating Boston Scientific facilities that hold them today. Raw recall counts are reported as filed and should always be read against installed base: a company with a larger fleet of complex, implantable Class III devices will generate more field corrections than a company focused on lower-risk supplies, so a high recall count is a reflection of product risk and scale, not a simple quality verdict. This methodology is the same one applied across our peer company profiles so the numbers are directly comparable.
Key Historical Milestones and M&A Impact
Boston Scientific's regulatory footprint is heavily defined by a history of strategic acquisitions that have expanded its product-code listings in cardiology, oncology, and neuromodulation. The table below outlines the key business integrations that shape its current registry profiles:
| Milestone / Acquisition | Year | Clinical Segment | Regulatory Significance |
|---|---|---|---|
| Guidant Acquisition ($27.2B) | 2006 | Cardiac Rhythm Management | One of the most competitive bidding wars in medtech history. Absorbed Guidant's pacemakers and defibrillators, adding a massive PMA and supplement footprint (product codes LWP and LWS). |
| Endosurgery Expansion | 2010s | Gastroenterology / Endoscopy | Expanded biliary drainage and stent listings (product code FGE) via continuous clearance updates. |
| BTG Acquisition ($4.2B) | 2019 | Interventional Oncology | Introduced specialty microcatheters, vascular accessories, and radioembolization spheres, expanding general surgery and oncology registrations. |
| Farapulse Acquisition ($295M) | 2021 | Electrophysiology | Brought the Farapulse Pulsed Field Ablation (PFA) system, introducing PFA catheter and generator listings. |
| Lumenis Surgical Acquisition | 2021 | Urology | Expanded the urological and laser therapy portfolio, introducing high-power surgical lasers under the General Surgery specialty. |
| Nalu Medical Partnership | 2024 | Pain Neuromodulation | Expanded listings for micro-sized spinal cord stimulators and peripheral nerve stimulators. |
| Silk Road Medical Acquisition ($1.2B) | 2024 | Vascular / Stroke Care | Introduced transcarotid artery revascularization (TCAR) systems, expanding peripheral vascular 510(k) clearances. |
| Bolt Medical Acquisition | 2025 | Cardiology | Acquired intravascular lithotripsy (IVL) systems, directly targeting peripheral and coronary calcium management clearances. |
The 510(k) Clearance Portfolio: Cardiovascular and Urology Dominance
As of June 2026, Boston Scientific holds 864 active 510(k) clearances. Segmenting these clearances by FDA medical specialty reveals a portfolio heavily concentrated in cardiovascular medicine and gastroenterology/urology, reflecting their focus on minimally invasive interventional devices:
| Medical Specialty | Clearance Count | Percentage of 510(k) Portfolio | Core Technologies |
|---|---|---|---|
| Cardiovascular | 397 | 45.9% | Peripheral angioplasty catheters, guide wires, diagnostic catheters, vascular embolization coils |
| Gastroenterology, Urology | 266 | 30.8% | Biliary stents, ureteral stents, lithotripsy systems, endoscopic dilation balloons, pelvic mesh |
| General, Plastic Surgery | 97 | 11.2% | Surgical lasers, RF ablation systems, tissue retractors, electrosurgical accessories |
| Neurology | 33 | 3.8% | Spinal cord stimulation electrodes, deep brain stimulator accessories, neurovascular guide wires |
| Radiology | 24 | 2.8% | Image-guided ablation systems, radiological imaging markers |
| Other Specialties | 47 | 5.5% | Anesthesiology tubes, general hospital sets, thoracic clamps |
| Total Active Clearances | 864 | 100.0% |
Detailed Product Code Directory: 510(k) Listings
The table below breaks down the top active 510(k) product codes held by Boston Scientific, illustrating their technical focus in catheter accessories and drainage devices:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Brand Families | Active Clearances |
|---|---|---|---|---|---|
| LIT | Cardiovascular | Class II (21 CFR 870.1250) | Peripheral Transluminal Angioplasty Catheter | Mustang, Coyote, Sterling | 68 |
| FGE | Gastroenterology | Class II (21 CFR 876.5012) | Biliary Duct Stents and Dilators | WallFlex, Axios, Wallstent | 65 |
| DQX | Cardiovascular | Class II (21 CFR 870.1280) | Catheter Guide Wire | V-18, Choice, Mailman | 47 |
| DQY | Cardiovascular | Class II (21 CFR 870.1250) | Percutaneous Catheter | Balloon dilation, access catheters | 38 |
| DQO | Cardiovascular | Class II (21 CFR 870.1200) | Diagnostic Intravascular Catheter | OptiCross imaging catheters | 28 |
| GBX | Gastroenterology | Class II (21 CFR 876.5010) | Biliary Stone Retrieval Device | SpyGlass, Trapezoid RX | 24 |
| FGB | Gastroenterology | Class II (21 CFR 876.5012) | Ureteral Stent | Polar Loop, Percuflex | 22 |
| ESW | General Surgery | Class II (21 CFR 878.5035) | Esophageal Prosthesis | WallFlex Esophageal Stents | 21 |
| GZB | Neurology | Class II (21 CFR 882.5850) | Spinal Cord Stimulator (Pain) | Precision, WaveWriter | 19 |
| NIP | Cardiovascular | Class II (21 CFR 870.3610) | Superficial Femoral Artery Stent | Eluvia, Innova stent systems | 18 |
Focus on Core 510(k) Product Categories
- LIT (Peripheral Angioplasty Catheters): Dilation balloons are crucial for opening occluded peripheral arteries. Boston Scientific's Mustang and Sterling lines are cleared under this category. Sourcing audits should focus on balloon burst pressure parameters, inflation/deflation timings, and compliance profiles.
- FGE (Biliary Stents and Dilators): Endoscopic urology and GI procedures require self-expanding metal stents (SEMS). WallFlex and Axios platforms are cleared under FGE. Key regulatory parameters include evaluating radial expansion forces, stent migration resistance, and packaging integrity.
- DQX (Guide Wires): Guide wires are the foundation of vascular access. Choice and V-18 guide wires are cleared here. Crucial parameters include core-to-tip transition profiles, hydrophilic coating durability, and torque transmission efficiency.
Premarket Approval (PMA) Portfolio: Focus on Pacemakers and Stents
Boston Scientific holds 6,725 PMA approvals and supplements, reflecting a substantial regulatory footprint in Class III medical devices. The company's PMA volume is driven by its cardiac rhythm management division (implanted pacemakers and defibrillators acquired via the Guidant transaction) and its interventional cardiology division (coronary drug-eluting stents), where every minor software update, electrode modification, or material change requires a formal PMA supplement.
Detailed PMA Product Code Directory
The table below outlines the high-risk Class III categories that dominate Boston Scientific's PMA approvals:
| Product Code | Specialty | Regulatory Classification | Device Description | Key Brand Families | Active PMA Filings |
|---|---|---|---|---|---|
| LWP | Cardiovascular | Class III (21 CFR 870.3610) | Pacemaker, Implantable (Non-CRT) | ACCOLADE, ESSENTIO, PROPONENT | 1,178 |
| LWS | Cardiovascular | Class III (21 CFR 870.3610) | Implantable Cardioverter Defibrillator | RESONATE, CHARISMA, MOMENTUM | 863 |
| NIQ | Cardiovascular | Class III (21 CFR 870.3680) | Coronary Drug-Eluting Stent | Synergy, Promus Premier | 641 |
| MAF | Cardiovascular | Class III (21 CFR 870.3680) | Stent, Coronary | Bare-metal coronary stents | 391 |
| LGW | Neurology | Class III (21 CFR 882.5850) | Spinal-Cord Stimulator, Totally Implanted | Precision, WaveWriter generators | 356 |
| NIK | Cardiovascular | Class III (21 CFR 870.3610) | CRT-D Defibrillator | RESONATE CRT-D, Cognis | 294 |
| NVZ | Cardiovascular | Class III (21 CFR 870.3610) | Pulse Generator, Permanent, Implantable | Implantable pacemaker generators | 264 |
| NVY | Cardiovascular | Class III (21 CFR 870.3680) | Permanent Defibrillator Electrodes | Reliance defibrillation leads | 212 |
| MFA | Cardiovascular | Class III (21 CFR 870.1250) | Laser Angioplasty / Lead Extraction | GlideLight laser sheaths | 185 |
| NVW | Cardiovascular | Class III (21 CFR 870.3680) | Pacemaker Electrode | CapSure, Guidant leads | 114 |
Major Clinical Trials and PMA Approvals
Boston Scientific's highest-risk Class III device clearances are grounded in landmark clinical trials that demonstrate clinical safety and long-term efficacy:
WATCHMAN Left Atrial Appendage Closure (LAAC) System
The WATCHMAN device is designed to reduce the risk of stroke in patients with non-valvular atrial fibrillation who need an alternative to oral anticoagulants.
- Clinical Evidence (PROTECT AF and PREVAIL Trials): The PMA approval of the WATCHMAN system was supported by two landmark randomized trials. The PROTECT AF trial (800 patients) and PREVAIL trial (407 patients) compared WATCHMAN against warfarin. The combined data demonstrated that WATCHMAN was non-inferior to warfarin for preventing ischemic stroke and systemic embolism, while showing a significant 85% reduction in hemorrhagic stroke and a 72% reduction in major bleeding after device endothelialization. Maintaining the WATCHMAN PMAs involves strict post-market registries (such as the LAAO Registry) to monitor device-related thrombus and peridevice leak parameters.
FARAPULSE Pulsed Field Ablation (PFA) System
The Farapulse platform represents a shift from thermal (radiofrequency or cryo) ablation to non-thermal cardiac tissue ablation for paroxysmal atrial fibrillation.
- Clinical Evidence (ADVENT Trial): The FDA clearance of Farapulse PFA was supported by the ADVENT trial, a randomized, controlled trial enrolling 607 patients. The study compared PFA against standard thermal ablation. Farapulse demonstrated equivalent efficacy (73.3% success vs. 71.3% for thermal) and an exceptional safety profile, showing zero device-related pulmonary vein stenosis or esophageal injury events—common complications of thermal systems. This trial supported rapid 510(k) and PMA clearances for the Farapulse generator and Farawave catheter platforms.
SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System
The SYNERGY Coronary Stent System is a major Class III PMA device platform designed to treat coronary artery disease by restoring blood flow while releasing the anti-restenotic drug everolimus.
- Clinical Evidence (EVOLVE Clinical Trial Program): The PMA approval of the SYNERGY stent was based on the landmark EVOLVE and EVOLVE II clinical trials. The EVOLVE II trial was a randomized, controlled, double-blind non-inferiority study enrolling 1,684 patients across global sites. It compared the SYNERGY stent (which features an ultra-thin abluminal bioabsorbable polymer that completely resorbs within 3 to 4 months) against the durable-polymer PROMUS Element Plus stent. The trial successfully met its primary endpoint, demonstrating non-inferiority in Target Lesion Failure (TLF) at 12 months (6.7% for SYNERGY vs. 6.5% for PROMUS).
- DAPT Duration Optimization (EVOLVE Short DAPT Trial): The EVOLVE Short DAPT trial evaluated the safety of a shortened, 3-month dual antiplatelet therapy (DAPT) regimen in high-bleeding-risk (HBR) patients implanted with the SYNERGY stent. In this prospective, multi-center study of 2,009 patients, discontinuing DAPT at 3 months was associated with exceptionally low rates of stent thrombosis (0.2% between months 3 and 12) and no increase in ischemic events, providing clinical rationale for shorter DAPT protocols in vulnerable patient populations.
WaveWriter Spinal Cord Stimulation (SCS) Systems
The WaveWriter Spinal Cord Stimulator is a Class III implantable neuromodulation platform engineered to manage chronic intractable pain.
- Clinical Evidence (COMBO Randomized Controlled Trial): The FDA approval and labeling for the WaveWriter system was heavily supported by the COMBO study, a Level I, prospective, multicenter randomized controlled trial. The study evaluated the clinical efficacy of "Combination Therapy" (simultaneously delivering sub-perception stimulation and paresthesia-based SCS) compared to paresthesia-based monotherapy. At 3 months, 88% of patients randomized to the Combination Therapy arm achieved the primary endpoint (a ≥50% reduction in overall pain from baseline without an increase in opioid use), compared to 71% in the monotherapy arm (p < 0.0001). These clinical benefits were sustained in long-term follow-ups, showing responder rates of 84% at 1 year and 85% at 2 years, along with significant improvements in quality of life.
Electrophysiology and Brain/Cerebral Protection
- Sentinel Cerebral Protection System: During Transcatheter Aortic Valve Replacement (TAVR), calcified debris can break loose from the aortic valve and migrate to the brain, causing a perioperative stroke. Boston Scientific's Sentinel system is a dual-filter protection device deployed via radial access to capture this debris. Cleared under the 510(k) pathway as a de novo classification, Sentinel is evaluated on its filter capture efficiency and clinical safety, showing a significant reduction in new brain lesions on MRI post-procedure.
- Specialty Endoscopy Solutions (SpyGlass and Axios): The Endoscopy division holds critical clearances for the SpyGlass DS Direct Visualization System. This micro-endoscope is passed through standard duodenoscopes to provide high-resolution direct visualization of the biliary and pancreatic ducts during ERCP procedures. The Axios stent and delivery system are cleared under a de novo pathway for endoscopic transmural drainage of pancreatic pseudocysts, representing a key clinical differentiator that bypasses open surgical drainage.
FDA Recalls and Safety Signals: Trends and Analysis
As of June 2026, FDA records associate 1,340 medical device recalls with Boston Scientific. This recall volume is concentrated in their highest-risk implantable cardiovascular and interventional product lines, reflecting the mechanical and electrical complexity of pacemakers, stents, and catheter delivery systems.
Annual Recall Trends (2020–2026)
Analyzing the year of initiation for Boston Scientific's recall records highlights the impact of product modifications and regulatory compliance actions:
| Year | Recall Volume | Core Product Lines Affected | Strategic Context & Regulatory Rationale |
|---|---|---|---|
| 2020 | 35 | Intravascular imaging catheters, guide wires | Catheter tip separations, guide wire coating peeling, packaging label discrepancies. |
| 2021 | 56 | Biliary stents (WallFlex), pacing leads | Stent delivery system failures, lead connector anomalies, software communication bugs. |
| 2022 | 41 | Eluvia drug-eluting stents, esophageal stents | Stent delivery hub cracks, stent migration risks, packaging sterility errors. |
| 2023 | 48 | Spinal cord stimulator controllers, sheaths | Remote control software errors, delivery sheath kinks, packaging damage. |
| 2024 | 98 | Pacemakers (ACCOLADE), telemetry tools | Spiked recall volume; battery manufacturing issues, telemetry security patches. |
| 2025 | 115 | Pacemaker safety mode, AXIOS stents, catheters | Battery software updates, AXIOS delivery system cracks, microcatheter leaks. |
| 2026 (Part) | 32 | Pacemakers (Brady SMR6), biliary dilators | Safety mode software update, dilator tip anomalies, labeling updates. |
Recall Distribution by Product Code
An analysis of Boston Scientific's recall registrations by product code reveals that pacemakers and biliary stents represent the highest frequency of recalls:
| Rank | Product Code | Device Category | Number of Recalls | Primary Recall Root Causes |
|---|---|---|---|---|
| 1 | LWP | Implantable Pacemaker | 98 | Battery software anomalies, premature battery depletion, safety mode entry |
| 2 | FGE | Biliary Stents / Drains | 75 | Delivery system deployment failures, stent migration risk, tissue adhesion |
| 3 | DQO | Intravascular Catheter | 75 | Catheter hub leakage, transducer signal drift, microcatheter tip separations |
| 4 | NIP | Femoral Stent (Eluvia) | 74 | Delivery catheter tip separations, stent deployment resistance, packaging damage |
| 5 | ESW | Esophageal Prosthesis | 65 | Stent delivery suture breaks, migration risk, mechanical integrity anomalies |
Recent 2025–2026 Class I Pacemaker Recall Case Studies
The most defining regulatory event for Boston Scientific in the 2025–2026 period is the Class I recall of certain ACCOLADE, ESSENTIO, PROPONENT, and ALTRUA 2 pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps):
- The Issue: The recall involves a software-related battery issue that can cause affected pacemakers to enter "Safety Mode" prematurely. In Safety Mode, the device's functionality is limited, reverting to backup pacing parameters and disabling advanced diagnostics. If this occurs, the pacemaker may fail to regulate the patient's heart rhythm properly, potentially resulting in serious injury or death.
- The Impact: As of March 18, 2026, Boston Scientific reported 2,557 serious injuries and four deaths associated with this safety mode issue.
- The Correction: Unlike recalls that require surgical removal of the device, this is a correction recall. Boston Scientific recommends that affected devices be upgraded with a software update (specifically the Brady SMR6 software) that corrects the battery monitoring algorithms and prevents premature entry into Safety Mode.
- Verification: Because model numbers alone do not identify all affected devices, Boston Scientific provides an online lookup tool (www.bostonscientific.com/lookup) for patients and physicians to verify if a specific serial number is impacted.
Notable Historical Recalls and Voluntary Withdrawals
- Lotus Edge Aortic Valve Voluntary Withdrawal (2020): In November 2020, Boston Scientific voluntarily withdrew its Lotus Edge Transcatheter Aortic Valve Replacement (TAVR) system from the global market. The decision was driven by complexities associated with the delivery system, specifically related to the mandrel release mechanism during deployment. Rather than pursuing a redesign, the company discontinued the product line to focus on its Acurate neo2 valve platforms.
- EmboShield NAV6 Embolic Protection Systems (2018): Boston Scientific recalled several thousand EmboShield systems due to risk of the filtration catheter tip separating during delivery, which could cause arterial damage or embolization. This event led to tighter QA controls over extrusion processes at its Coventry facility.
- WallFlex Duodenal Stent Field Actions (2021): Recalls were issued for WallFlex duodenal stents following reports of deployment failure where the stent failed to release cleanly from the catheter sheath, necessitating design changes to the delivery wire coating.
Sub-tier Supplier and CDMO Quality Controls
Operating high-precision interventional manufacturing lines requires meticulous control over suppliers:
- Cleanroom Assembly CDMOs: Catheter extrusion and stent mounting are performed in Class 10,000 (ISO 7) or Class 100,000 (ISO 8) cleanrooms. Boston Scientific audits its contract manufacturing organizations (CDMOs) for microbial bioburden counts, particulate monitoring compliance, and HVAC filtration integrity. Sourcing agreements require detailed cleanroom qualification reports (IQ/OQ/PQ) for any lines processing cardiovascular components.
- Sterilization Validation: Almost all interventional catheters are sterilized using Ethylene Oxide (EtO) or Gamma irradiation. Boston Scientific audits sterilization vendors to verify compliance with ISO 11135 (for EtO) and ISO 11137 (for radiation) standards. Supplier corrective actions are generated for any cycle temperature deviations or packaging integrity failures.
- Battery Cell and Capacitor Sourcing: For pacemakers, Boston Scientific contracts with audited electronics component suppliers to source high-grade lithium batteries and high-voltage capacitors. Quality agreements dictate strict incoming inspection criteria, including capacitance drift limits and internal leakage tests, to prevent sudden battery depletion events.
Cybersecurity and Software Bill of Materials (SBOM) Compliance
In the electrophysiology suite, programming consoles and telemetry monitors are connected to clinical networks:
- Software Bill of Materials (SBOM): Boston Scientific maintains comprehensive SBOMs for software-driven platforms like the LATITUDE patient management system and ZOOM programming consoles. These registries detail all software components, including open-source communication libraries and embedded database engines, allowing hospital IT teams to verify vulnerability exposure.
- Incident Response & PSIRT: The company runs a Product Security Incident Response Team (PSIRT) that actively monitors for vulnerabilities. When security gaps are identified, the PSIRT collaborates with clinical software teams to issue patches and publishes coordinated vulnerability disclosures (CVDs).
- Network Integration Support: Sourcing teams must audit the device's Manufacturer Disclosure Statement for Medical Device Security (MDS2) to ensure compliance with hospital cybersecurity gates, focusing on data-at-rest encryption, wireless transmission security, and local audit trail logging.
European MDR Transition and Portfolio Rationalization
The implementation of the European MDR (Regulation 2017/745) has reshaped Boston Scientific's European footprint:
- Portfolio Rationalization: High clinical data requirements under MDR have led Boston Scientific to rationalize its catalog in Europe. The company has allowed legacy balloon catheter variants, specific guide wire lengths, and older biliary stent models to expire from European distribution, focusing resources on current-generation platforms like the Synergy stent and Axios systems.
- Galway Notified Body Coordination: Boston Scientific coordinates technical file submissions from its Galway, Ireland facility with European Notified Bodies (such as TÜV SÜD and BSI). The company has leveraged extension timelines to ensure that high-volume interventional platforms remain cleared while transition documentation is reviewed.
Sourcing Decision Guide: Hospital Sourcing Matrix
Clinical engineering and hospital value-analysis committees (VAT) should use the following decision matrix when auditing Boston Scientific as a primary vendor:
[Boston Scientific Footprint Audit Workflow]
│
┌──────────────────────┴──────────────────────┐
(Class III CRM/Defib) (Class II MedSurg/Catheters)
│ │
Verify specific PMA supplement history Evaluate remote software patch capabilities
│ │
Audit site-specific FDA warning history Confirm backup inventory for logistics nodes
(e.g., Saint Paul CRM vs. Galway Stents) (e.g., Coventry urology vs. Galway stents)
│ │
┌─────────────┴─────────────┐ │
│ Verify SMR6 software │ │
│ update rollout timing │ │
└─────────────┬─────────────┘ │
└──────────────────────┬──────────────────────┘
▼
Define standard uptime SLAs
(Exclude remote software patches)
Sourcing Decision Matrix:
- Implantable Pacemakers & Defibrillators (Class III CRM):
- Audit Objective: Verify compliance with the Brady SMR6 software patch rollout.
- Decision Rule: Do not source pacemakers or CRT-Ps from lots affected by the 2026 safety mode recall unless the vendor certifies the firmware has been updated to SMR6 prior to shipment.
- Contract SLA: Implement a performance penalty if the vendor fails to provide on-site technical support for firmware updates within 48 hours of a clinical request.
- Drug-Eluting Stents & Balloons (Class III Interventional):
- Audit Objective: Audit Galway, Ireland manufacturing and shipping timelines.
- Decision Rule: Ensure the vendor maintains at least a 60-day safety stock in US distribution centers to mitigate European shipping delays.
- Contract SLA: Require immediate substitution options for back-ordered coronary stent models at no additional charge.
- Urological & Endoscopic Accessories (Class II MedSurg):
- Audit Objective: Evaluate mechanical failure rates of biliary dilators and guide wires.
- Decision Rule: Audit lot-specific recall logs for WallFlex and Axios systems prior to standardizing across a hospital network.
- Contract SLA: Mandate replacement or credit for any delivery catheter that experiences tip separation or deployment failure in the procedural suite.
Establishment Registrations and Global Manufacturing Footprint
To distribute medical devices in the United States, manufacturers must register their facilities and list all devices processed at those locations. Boston Scientific has 2,399 active establishment registration and device listings associated with its operating facilities.
Analyzing Boston Scientific's listings by city reveals its primary manufacturing, distribution, and logistics hubs:
- Saint Paul, Minnesota, USA (531 listings): Boston Scientific's primary center for cardiac rhythm management (pacemakers and defibrillators), electrophysiology, and clinical software development.
- Coventry, Rhode Island, USA (391 listings): A major manufacturing site for urology and pelvic health devices, catheter subassemblies, and extrusion components.
- Galway, Ireland (332 listings): Boston Scientific's largest offshore manufacturing site. This facility is a global hub for interventional cardiology and structural heart devices, manufacturing drug-eluting stents (Synergy), balloon catheters, and heart valves.
- Marlborough, Massachusetts, USA (256 listings): Boston Scientific's global corporate headquarters, housing key R&D facilities for endoscopy and peripheral interventions, as well as corporate administration.
- Maple Grove, Minnesota, USA (182 listings): A key manufacturing site for interventional cardiology products, including balloon catheters, guide wires, and stent delivery systems.
Boston Scientific Global Manufacturing Concentration
The geographic distribution of Boston Scientific's listings reveals a model focused on high-end US manufacturing combined with a major European hub in Ireland:
| Region | Listing Count | Percentage of Listings | Core Capabilities |
|---|---|---|---|
| United States (Saint Paul, Coventry, Marlborough, Maple Grove) | 1,360 | 56.7% | Cardiac rhythm management, urology, endoscopy R&D, corporate administration |
| Ireland (Galway) | 332 | 13.8% | Drug-eluting stents, balloon catheters, structural heart manufacturing |
| Other Facilities (Heredia, Costa Rica; Penang, Malaysia, etc.) | 707 | 29.5% | Offshore assembly, global distribution, local manufacturing |
| Total Listings | 2,399 | 100.0% |
How Boston Scientific Compares With Peers
Boston Scientific's regulatory footprint is best understood alongside its medical device industry peers. The table below places Boston Scientific against major competitors across key FDA database metrics:
| Regulatory Metric | Medtronic | Boston Scientific | Abbott | GE HealthCare | Siemens Healthineers | Philips |
|---|---|---|---|---|---|---|
| Active 510(k) clearances | 1,597 | 864 | 1,218 | 1,680 | 1,573 | 1,322 |
| PMA approvals / supplements | 12,805 | 6,725 | 5,617 | 95 | 540 | 350 |
| FDA-registered recalls | 1,897 | 1,340 | 909 | 1,490 | 2,042 | 2,397 |
| Establishment / device listings | 7,855 | 2,399 | 2,393 | 5,512 | 4,114 | 5,180 |
| Leading 510(k) product code | NKB (Spine, 104) | LIT (Peripheral, 68) | FRN (Infusion Pump, 69) | IYN (Ultrasound, 179) | JAK (CT, 155) | LNH (MRI, 125) |
| PMA portfolio focus | ICDs & pacemakers (LWS, 1,463) | Pacemakers (LWP, 1,178) | CRT-D Defibrillators (NIK, 489) | Breast imaging (MUE, 37) | In-vitro diagnostics (LOM, 189) | Laser angioplasty (LPC, 124) |
Common Pitfalls When Auditing a Boston Scientific Footprint
Vendor audits of Boston Scientific's regulatory profile often fail due to predictable oversights:
- Overlooking Software Corrections: In modern electrophysiology, recalls are frequently resolved via software updates (such as the Brady SMR6 software update for pacemakers) rather than surgical device removal. When reviewing recall logs, auditors must distinguish between device removals and software corrections to avoid unnecessary clinical alarms.
- Ignoring Subsidiary and Acquired Registrations: Boston Scientific's footprint includes legacy Guidant CRM registrations, BTG interventional lines, and newer acquisitions (such as Nalu, Bolt Medical, and Farapulse). Searching solely under the parent name "Boston Scientific" will result in an incomplete audit.
- Failing to Verify Device Lookup Tools: For complex pacemakers subject to recalls (like the ACCOLADE series), relying on broad model numbers can lead to confusion. Auditors must use Boston Scientific's dedicated device lookup tool with specific serial numbers to verify affected inventory.
- Neglecting Galway Supply Chain Dependencies: Because Galway, Ireland serves as the primary global hub for Boston Scientific's drug-eluting stents and balloon catheters, supply continuity audits must evaluate logistics corridors and European regulatory updates affecting this Irish facility.
Frequently Asked Questions (FAQ)
What is the most common medical specialty for Boston Scientific 510(k) clearances?
Cardiovascular devices represent the largest portion of Boston Scientific's active 510(k) clearances, accounting for 397 clearances (45.9%), followed by Gastroenterology and Urology devices with 266 clearances (30.8%), reflecting their focus on peripheral interventions, stents, and urological access.
Where are Boston Scientific's primary FDA-registered manufacturing hubs?
Boston Scientific's primary registered hubs by listing count are in Saint Paul, Minnesota (531 listings for pacemakers and defibrillators), Coventry, Rhode Island (391 listings for urology manufacturing), and Galway, Ireland (332 listings for interventional cardiology and drug-eluting stents).
How many FDA recalls are associated with Boston Scientific?
As of June 2026, FDA records associate 1,340 recalls with Boston Scientific. These are heavily concentrated in cardiac rhythm management (pacemakers, ICDs) and interventional devices, reflecting their complex electrical and mechanical designs.
What is the status of the Boston Scientific ACCOLADE pacemaker recall?
The FDA classified the safety mode entry issue in ACCOLADE, ESSENTIO, PROPONENT, and ALTRUA 2 pacemakers as a Class I recall in March 2026. This is a correction recall resolved by upgrading the device firmware using the Brady SMR6 software update, rather than surgically removing the implanted device.
Does Boston Scientific's lookup tool cover all recalled pacemakers?
Yes, Boston Scientific provides a dedicated online serial number lookup tool at www.bostonscientific.com/lookup to help clinicians and patients verify if their specific pacemaker or CRT-P device requires the Brady SMR6 software update.
Why did Boston Scientific withdraw the Lotus Edge TAVR valve?
The company withdrew the Lotus Edge system in 2020 due to complexities with the catheter delivery release mechanism. Instead of redesigning the delivery tool, they focused capital on their Acurate neo2 valve lines.
Are urology mesh systems still registered in Boston Scientific's FDA footprint?
Yes, Boston Scientific maintains registrations for specific pelvic mesh lines used for incontinence and prolapse, though they are subject to strict post-market clinical surveillance guidelines following historic class actions.
What does product code LIT represent in Boston Scientific's 510(k) profile?
Product code LIT represents transluminal peripheral angioplasty catheters (Class II, 21 CFR 870.1250). These balloons are used to dilate stenotic peripheral blood vessels in peripheral arterial disease treatments.
How does the Galway site impact supply chain risk?
As the primary global manufacturing hub for drug-eluting stents and cardiovascular balloons, any local warning letters or transport disruptions at the Galway facility could affect U.S. clinical supply, making regional stock verification crucial.
What clinical trials support the WATCHMAN device PMA?
The WATCHMAN system PMA was supported by the PROTECT AF and PREVAIL trials, which demonstrated WATCHMAN was non-inferior to warfarin for stroke prevention while significantly reducing hemorrhagic stroke and bleeding risks.
Educational Disclaimer
This regulatory dossier is provided for educational and informational purposes only. It is based on computed aggregates of public FDA database extracts from June 2026 and should not be construed as legal, regulatory, clinical, quality system, or reimbursement advice for any specific product, clinical protocol, or commercial transaction.